Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Fifty years of beta-blockers: a revolution in CV pharmacotherapy William H. Frishman, MD, MACP
• JUPITER trial results: Using hsCRP to identify primary prevention patients who may benefit from statin therapy Roger S. Blumenthal, MD; Catherine Y. Campbell, MD
• Nonprofit hospitals buying up cardiology practices L. Samuel Wann, MD, MACC, FESC
• ASE consensus statement reaffirms importance of ultrasound contrast agents
• Atherosclerosis still present in patients with calcium score of zero
• ATLAS TIMI 46: Rivaroxaban did not lower endpoint of death, MI, stroke, severe ischemia requiring revascularization
• CARESS: no difference between carotid endarterectomy and stenting
• Data insufficient for routine CAC screening
• Dual-source CTA comparable with catheter angiogram for CAD diagnosis
• Elderly patients hospitalized for MI are at elevated risk for developing subsequent HF
• FDA seizes contaminated heparin lots in Cincinnati
• HF-ACTION: Exercise program yielded modest benefit for patients with HF
• HORIZONS AMI: Results support bivalirudin
• I-PRESERVE: No reduction in mortality in patients with HF
• JPAD: Low-dose aspirin did not prevent CV events in Japanese patients with type 2 diabetes
• Major adverse cardiac events can be ruled out by coronary CTA in some patients
• Minority children more likely to die waiting for heart transplants than white children
• Panel recommends FDA approval of ThermoCool ablation catheter
• Patients with HF may have more doctor visits than average Medicare beneficiary
• Risk for sudden cardiac death increased in month following MI
• Statins in the water? Not yet
• The X-ray: providing a new perspective in 1895
• Chugh named head of Cedars-Sinai Heart Institute
• Peter Libby, MD, says shifting demographics will shape the future of cardiology
• SSRIs recommended for patients with CHD, depression Rhonda Cooper-DeHoff, PharmD